利妥昔单抗治疗甲状腺相关眼病的系统评价

The relationship between thyroid associated ophthalmopathy and rituximab： a systematic review

目的系统评价利妥昔单抗（RTX）治疗甲状腺相关眼病（TAO）的有效性和安全性。方法计算机检索PUBMED、EMbase、中国知网、维普和万方数据平台等，从2006年1-3月，选择利妥昔单抗治疗甲状腺相关眼病的随机对照试验（RCT）或队列研究试验。评价纳入文献质量，进行系统评价。结果共纳入2个RCT，4个队列研究，结果进行描述性分析。l篇RCT研究质量较好，明确指出RTX对中重度TAO患者有显著的疗效，并且不良反应较小。另l篇RCT研究提出RTX对中重度TAO患者无显著的疗效，且出现严重的视神经病变的不良反应。4项队列研究中均指出RTX治疗TAO患者有显著疗效，但未详细描述治疗后的不良反应。结论鉴于本系统评价纳入研究较少且样本含量较小，因此未来尚需开展更多大样本、多中心、设计严格的高质量RCT加以验证。

Objective To systematically evaluate the relationship between thyroid associated ophthalmopathy （TAO） and rituximab （RTX）. Methods We electronically searched the CNKI, Cqvip, WanFang Data, PubMed, and EMbase databases to collected randomized controlled trials （RCTs） or cohort study about the association between thyroid associated ophthalmopathy and rituximab from January 2006 to March 2016. Two reviewers independently screened literature according to the inclusion and exclusion criteria. Results A total of 6 studies were included in the systematic review. All studies showed flint rituximab could be used to treat thyroid associated ophthalmopathy. Conclusion Due to the small sample size in this Meta analysis, more RCTs of high quality and large scale axe needed to be performed in the future.